Drug intelligence / Profile preview

doxycycline + metronidazole + cefdinir

Development stage
Unknown
Lead developer
Pfizer
Modality
Small Molecules
Administration
Oral
01

Overview

This is a combination of three antibiotics—doxycycline, metronidazole, and cefdinir. Each component has a distinct mechanism of action and antimicrobial spectrum: - Doxycycline is a tetracycline-class antibiotic that inhibits bacterial protein synthesis by binding to the 30S ribosomal subunit. It is active against a wide range of gram-positive and gram-negative bacteria, as well as atypical organisms[3]. - Metronidazole is a nitroimidazole antibiotic that disrupts DNA synthesis in anaerobic bacteria and certain protozoa by generating free radicals after reduction within the microbial cell[2][6]. - Cefdinir is an oral third-generation cephalosporin (beta-lactam) antibiotic that inhibits bacterial cell wall synthesis by binding to penicillin-binding proteins, leading to cell lysis. It covers many gram-positive and some gram-negative organisms[7][10]. This combination would provide broad-spectrum coverage against aerobic, anaerobic, gram-positive, and gram-negative pathogens. Such combinations are not standard but may be considered in complex or mixed infections where multiple types of bacteria are suspected or confirmed.

02

Targets

Bacterial RibosomeNeuraminidasePBP (Penicillin-binding protein family)

Beyond the preview

Go deeper on doxycycline + metronidazole + cefdinir.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Full profile access

Follow clinical development from study design and recruitment through results.

  • Trial phase
  • Status
  • Readouts

Indications & development

Full profile access

Explore development by indication, patient population, and geography.

  • Indications
  • Development status
  • Countries

Licensing & deals

Full profile access

Trace asset ownership, licensing agreements, and commercial partnerships.

  • Partners
  • Deal terms
  • Milestones

Patents & exclusivity

Full profile access

Explore the patent landscape and regulatory exclusivity around an asset.

  • Patents
  • Expiration dates
  • Exclusivity

Competitive landscape

Full profile access

Compare development programs by target, modality, and indication.

  • Competing assets
  • Targets
  • Development stage

Research & analysis

Full profile access

Connect source evidence and development news to your research questions.

  • Publications
  • News
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on doxycycline + metronidazole + cefdinir.

Explore the full profile

Gosset Free

Get started with Gosset.

Enter your work email and we’ll be in touch with next steps.

Work email preferred.

Book a call